Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca's Strategic Focus and Clinical Trial Success Bolster Buy Rating
AstraZeneca (AZN) Receives a Buy From Goldman Sachs
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
AstraZeneca (AZN) Receives a Buy From Barclays
AstraZeneca Analyst Ratings
Berenberg Trims Price Target on AstraZeneca to GBP140 From GBP150, Keeps Buy Rating
AstraZeneca Raised to Neutral From Sell by UBS
Berenberg Bank Sticks to Their Buy Rating for AstraZeneca (AZN)
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $87
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
TD Cowen Remains a Buy on AstraZeneca (AZN)
Kepler Capital Remains a Hold on AstraZeneca (AZN)
DZ BANK AG Keeps Their Hold Rating on AstraZeneca (AZN)
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Cuts Target Price to $88
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating
Barclays Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca Raised to Buy From Hold by Intron Health
AstraZeneca (AZN) Gets a Hold From Jefferies